# Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

> **NCT00477594** · PHASE2 · COMPLETED · sponsor: **Kastle Therapeutics, LLC** · enrollment: 21 (actual)

## Conditions studied

- Lipid Metabolism, Inborn Errors
- Hypercholesterolemia, Autosomal Dominant
- Hyperlipidemias
- Metabolic Diseases
- Hyperlipoproteinemia Type II
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Infant, Newborn, Diseases
- Metabolic Disorder
- Congenital Abnormalities
- Hypercholesterolemia
- Hyperlipoproteinemias
- Dyslipidemias
- Lipid Metabolism Disorders

## Interventions

- **DRUG:** mipomersen sodium

## Key facts

- **NCT ID:** NCT00477594
- **Lead sponsor:** Kastle Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2011-03
- **Final completion:** 2011-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2016-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00477594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00477594, "Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00477594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*